Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now

Motley Fool04-22

One of these magnificent stocks could be a big winner in a new $4 trillion market. Another is a leader in using AI to automate online processes. The third is a biotech with multiple ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

百事可乐201609
04-23
百事可乐201609
说说你对这篇新闻的看法...

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429943483?lang=zh_CN&edition=full","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773509%2Fwoman-smiling-laptop.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-04-22 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429943483","market":"us","top_or_hot":-1,"title":"Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now","media":"Motley Fool","content":"<div>\n<p>One of these magnificent stocks could be a big winner in a new $4 trillion market.\n\n\n\n\n\n\n\nAnother is a leader in using AI to automate online processes.\n\n\n\n\n\n\n\nThe third is a biotech with multiple ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLooking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of these magnificent stocks could be a big winner in a new $4 trillion market.\n\n\n\n\n\n\n\nAnother is a leader in using AI to automate online processes.\n\n\n\n\n\n\n\nThe third is a biotech with multiple ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B1BXHZ80.USD","symbol_name":"Legg Mason ClearBridge - US Appreciation A Acc USD","start_time":0,"source_url":"https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/","article_id":"2429943483","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773509%2Fwoman-smiling-laptop.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429943483","pubTimestamp":1713779520,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These stocks could be near major inflection points.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","VRTX":"福泰制药","LU0971096721.USD":"富达环球金融服务 A","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","OXY":"西方石油","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0149725797.USD":"汇丰美国股市经济规模基金","CF":"CF工业","VERX":"Vertex, Inc.","DAC":"达那俄斯","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BRK.A":"伯克希尔","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BRK.B":"伯克希尔B","BK4550":"红杉资本持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0079474960.USD":"联博美国增长基金A","BK4551":"寇图资本持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4097":"系统软件","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","PATH":"UiPath","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4093":"化肥与农用药剂","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4176":"多领域控股","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4201":"综合性石油与天然气企业","BK4532":"文艺复兴科技持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"寻找一代人一次的投资机会？这里有3只非常棒的股票，现在就可以买","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAC":1,"CF":1,"VRTX":0.9,"BRK.B":0.9,"PATH":0.9,"OXY":0.9,"VERX":0.81,"BRK.A":0.71},"content_text":"One of these magnificent stocks could be a big winner in a new $4 trillion market.\n\n\n\n\n\n\n\nAnother is a leader in using AI to automate online processes.\n\n\n\n\n\n\n\nThe third is a biotech with multiple potentially game-changing therapies in development.\n\nI disagree with the adage that \"opportunity only knocks once.\" At least, I don't think it's always true with investing. That said, there are inflection points for some stocks after which things will never be the same.Looking for these kinds of once-in-a-generation investment opportunities? Here are three magnificent stocks to buy right now.1. Occidental PetroleumYou might be surprised to see an oil stock on this list. Aren't companies based on fossil fuels in danger of becoming fossils themselves? Not if Occidental Petroleum (OXY 0.89%) has its way.Occidental is at the forefront of developing direct air capture (DAC) technology. DAC extracts carbon dioxide directly from the air. Oxy CEO Vicki Hollub's goal is to produce \"net-zero\" oil where the CO2 captured in the production of the oil effectively cancels out the emissions produced by using the oil. Hollub believes if DAC fulfills its potential, her company will be able to \"produce oil and gas forever.\" Carbon capture could also open up a massive new opportunity for Occidental and other pioneers. ExxonMobil projects a carbon capture and storage market of $4 trillion by 2050. Unsurprisingly, the oil and gas giant is also investing heavily in the technology. Occidental is potentially at another inflection point as well. Warren Buffett's Berkshire Hathaway currently owns 28% of the company. Buffett has made clear Berkshire doesn't want to acquire Oxy. However, I suspect the conglomerate will continue to aggressively buy shares of the oil producer -- especially considering Berkshire secured regulatory approval to purchase up to 50% of the company. Occidental could become a near-subsidiary of the conglomerate even if doesn't have majority ownership. 2. UiPathI think artificial intelligence (AI) will create many once-in-a-generation investment opportunities. And those opportunities aren't limited to the tech giants that typically capture the headlines. UiPath (PATH -1.52%) is a much smaller company with a market cap of under $11 billion that could be on the threshold of a new era.UiPath is a leader in robotic process automation (RPA). The idea behind RPA is to automate online tasks to improve productivity. RPA isn't new: UiPath was founded in 2005. However, generative AI could be a game-changer that leads to explosive growth. A recent survey UiPath conducted with consulting firm Bain found that 70% of corporate executives believe AI-driven automation is \"very important\" or \"critical\" to the future of their industry. Eighty-four percent of executives believe AI \"will radically change how businesses operate in the next five (5) years.\" UiPath is seizing this opportunity. The company recently launched preview versions of its AI-powered Autopilot for Studio product for developing process automation using natural language and Autopilot for Test Suite to improve productivity in testing. In March, UiPath introduced new generative AI capabilities for its platform. 3. Vertex PharmaceuticalsVertex Pharmaceuticals (VRTX 0.20%) commands a monopoly in treating the underlying cause of cystic fibrosis (CF). It's in the early stages of the commercial launch of the first CRISPR gene-editing therapy, a one-time cure for two rare blood disorders. But those aren't why I think this biotech stock is a once-in-a-generation investment opportunity.The company could have another megablockbuster franchise waiting in the wings in treating pain. Vertex plans to file for regulatory approval of non-opioid pain drug VX-548 this summer and is already preparing for a near-term commercial launch. VX-548 could fill a big gap between anti-inflammatory drugs that are safe but not as effective and opioids that are effective but highly addictive. The biotech is also evaluating other promising non-opioid pain therapies in phase 1 and 2 clinical studies. Vertex recently advanced inaxaplin into phase 3 testing for treating APOL1-mediated kidney disease (AMKD). It hopes to seek accelerated approval if an interim analysis at week 48 of the study looks good. There are no approved therapies that treat the underlying cause of AMKD. The disease affects more patients than CF. There's more. Vertex's pipeline includes programs that hold the potential to cure type 1 diabetes. The company also recently announced the planned acquisition of Alpine Immune Sciences. Alpine expects to advance its lead candidate povetacicept into late-stage testing later this year in treating IgA nephropathy, another disease that affects more patients than CF and with no approved therapies for treating the underlying cause.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":298196453998760,"gmtCreate":1713830703933,"gmtModify":1713830705363,"author":{"id":"3434867142275235","authorId":"3434867142275235","name":"百事可乐201609","avatar":"https://static.tigerbbs.com/0aaa8223dd39339e7a15377ab5da1793","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":7,"crmLevelSwitch":1},"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/298196453998760","repostId":2429943483,"repostType":2,"repost":{"id":"2429943483","pubTimestamp":1713779520,"share":"https://www.laohu8.com/m/news/2429943483?lang=&edition=full","pubTime":"2024-04-22 17:52","market":"us","language":"en","title":"Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2429943483","media":"Motley Fool","summary":"These stocks could be near major inflection points.","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>One of these magnificent stocks could be a big winner in a new $4 trillion market.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Another is a leader in using AI to automate online processes.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>The third is a biotech with multiple potentially game-changing therapies in development.</div>\n</li>\n</ul><div><p>I disagree with the adage that \"opportunity only knocks once.\" At least, I don't think it's always true with investing. That said, there are inflection points for some stocks after which things will never be the same.</p><p>Looking for these kinds of once-in-a-generation investment opportunities? Here are three magnificent stocks to buy right now.</p><h2>1. Occidental Petroleum</h2><p>You might be surprised to see an oil stock on this list. Aren't companies based on fossil fuels in danger of becoming fossils themselves? Not if <strong>Occidental Petroleum</strong> <span>(OXY<span> 0.89%</span>)</span> has its way.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"204875\" :show_benchmark_compare=\"false\" amount_change=\"0.59\" average_volume=\"8,603,691\" company_name=\"Occidental Petroleum\" current_price=\"66.63\" daily_high=\"67.62\" daily_low=\"66.12\" default_period=\"OneYear\" dividend_yield=\"1.14%\" exchange=\"NYSE\" fifty_two_week_high=\"71.19\" fifty_two_week_low=\"55.12\" gross_margin=\"34.39\" logo=\"https://g.foolcdn.com/art/companylogos/mark/OXY.png\" market_cap=\"$59B\" pe_ratio=\"17.07\" percent_change=\"0.89\" symbol=\"OXY\" volume=\"27,318\"></app></div><p>Occidental is at the forefront of developing direct air capture (DAC) technology. DAC extracts carbon dioxide directly from the air. Oxy CEO Vicki Hollub's goal is to produce \"net-zero\" oil where the CO2 captured in the production of the oil effectively cancels out the emissions produced by using the oil. Hollub believes if DAC fulfills its potential, her company will be able to \"produce oil and gas forever.\" </p><p>Carbon capture could also open up a massive new opportunity for Occidental and other pioneers. <strong>ExxonMobil</strong> projects a carbon capture and storage market of $4 trillion by 2050. Unsurprisingly, the oil and gas giant is also investing heavily in the technology. </p><div><div></div></div><p>Occidental is potentially at another inflection point as well. Warren Buffett's <strong>Berkshire Hathaway</strong> currently owns 28% of the company. Buffett has made clear Berkshire doesn't want to acquire Oxy. However, I suspect the conglomerate will continue to aggressively buy shares of the oil producer -- especially considering Berkshire secured regulatory approval to purchase up to 50% of the company. Occidental could become a near-subsidiary of the conglomerate even if doesn't have majority ownership. </p><h2>2. <a href=\"https://laohu8.com/S/PATH\">UiPath</a></h2><p>I think artificial intelligence (AI) will create many once-in-a-generation investment opportunities. And those opportunities aren't limited to the tech giants that typically capture the headlines. <strong>UiPath</strong> <span>(PATH<span> -1.52%</span>)</span> is a much smaller company with a market cap of under $11 billion that could be on the threshold of a new era.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"344297\" :show_benchmark_compare=\"false\" amount_change=\"-0.29\" average_volume=\"9,075,075\" company_name=\"UiPath\" current_price=\"18.75\" daily_high=\"19.07\" daily_low=\"18.57\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NYSE\" fifty_two_week_high=\"27.87\" fifty_two_week_low=\"12.38\" gross_margin=\"84.81\" logo=\"https://g.foolcdn.com/art/companylogos/mark/PATH.png\" market_cap=\"$11B\" pe_ratio=\"-115.81\" percent_change=\"-1.52\" symbol=\"PATH\" volume=\"3,330\"></app></div><p>UiPath is a leader in robotic process automation (RPA). The idea behind RPA is to automate online tasks to improve productivity. RPA isn't new: UiPath was founded in 2005. However, generative AI could be a game-changer that leads to explosive growth. </p><p>A recent survey UiPath conducted with consulting firm Bain found that 70% of corporate executives believe AI-driven automation is \"very important\" or \"critical\" to the future of their industry. Eighty-four percent of executives believe AI \"will radically change how businesses operate in the next five (5) years.\" </p><div><div></div></div><p>UiPath is seizing this opportunity. The company recently launched preview versions of its AI-powered Autopilot for Studio product for developing process automation using natural language and Autopilot for Test Suite to improve productivity in testing. In March, UiPath introduced new generative AI capabilities for its platform. </p><h2>3. Vertex Pharmaceuticals</h2><p><strong>Vertex Pharmaceuticals</strong> <span>(VRTX<span> 0.20%</span>)</span> commands a monopoly in treating the underlying cause of cystic fibrosis (CF). It's in the early stages of the commercial launch of the first CRISPR gene-editing therapy, a one-time cure for two rare blood disorders. But those aren't why I think this biotech stock is a once-in-a-generation investment opportunity.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"206020\" :show_benchmark_compare=\"false\" amount_change=\"0.80\" average_volume=\"1,214,761\" company_name=\"Vertex Pharmaceuticals\" current_price=\"394.28\" daily_high=\"396.98\" daily_low=\"391.25\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"448.40\" fifty_two_week_low=\"316.43\" gross_margin=\"87.17\" logo=\"https://g.foolcdn.com/art/companylogos/mark/VRTX.png\" market_cap=\"$102B\" pe_ratio=\"28.38\" percent_change=\"0.20\" symbol=\"VRTX\" volume=\"13\"></app></div><p>The company could have another megablockbuster franchise waiting in the wings in treating pain. Vertex plans to file for regulatory approval of non-opioid pain drug VX-548 this summer and is already preparing for a near-term commercial launch. VX-548 could fill a big gap between anti-inflammatory drugs that are safe but not as effective and opioids that are effective but highly addictive. The biotech is also evaluating other promising non-opioid pain therapies in phase 1 and 2 clinical studies. </p><p>Vertex recently advanced inaxaplin into phase 3 testing for treating APOL1-mediated kidney disease (AMKD). It hopes to seek accelerated approval if an interim analysis at week 48 of the study looks good. There are no approved therapies that treat the underlying cause of AMKD. The disease affects more patients than CF. </p><div><div></div></div><p>There's more. Vertex's pipeline includes programs that hold the potential to cure type 1 diabetes. The company also recently announced the planned acquisition of <strong>Alpine Immune Sciences</strong>. Alpine expects to advance its lead candidate povetacicept into late-stage testing later this year in treating IgA nephropathy, another disease that affects more patients than CF and with no approved therapies for treating the underlying cause. </p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLooking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 17:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One of these magnificent stocks could be a big winner in a new $4 trillion market.\n\n\n\n\n\n\n\nAnother is a leader in using AI to automate online processes.\n\n\n\n\n\n\n\nThe third is a biotech with multiple ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F773509%2Fwoman-smiling-laptop.jpg&op=resize&w=165&h=104","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","VRTX":"福泰制药","LU0971096721.USD":"富达环球金融服务 A","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","OXY":"西方石油","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0149725797.USD":"汇丰美国股市经济规模基金","CF":"CF工业","VERX":"Vertex, Inc.","DAC":"达那俄斯","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BRK.A":"伯克希尔","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BRK.B":"伯克希尔B","BK4550":"红杉资本持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0079474960.USD":"联博美国增长基金A","BK4551":"寇图资本持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4097":"系统软件","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","PATH":"UiPath","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4093":"化肥与农用药剂","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4176":"多领域控股","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4201":"综合性石油与天然气企业","BK4532":"文艺复兴科技持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"source_url":"https://www.fool.com/investing/2024/04/22/once-in-a-generation-investment-stocks-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2429943483","content_text":"One of these magnificent stocks could be a big winner in a new $4 trillion market.\n\n\n\n\n\n\n\nAnother is a leader in using AI to automate online processes.\n\n\n\n\n\n\n\nThe third is a biotech with multiple potentially game-changing therapies in development.\n\nI disagree with the adage that \"opportunity only knocks once.\" At least, I don't think it's always true with investing. That said, there are inflection points for some stocks after which things will never be the same.Looking for these kinds of once-in-a-generation investment opportunities? Here are three magnificent stocks to buy right now.1. Occidental PetroleumYou might be surprised to see an oil stock on this list. Aren't companies based on fossil fuels in danger of becoming fossils themselves? Not if Occidental Petroleum (OXY 0.89%) has its way.Occidental is at the forefront of developing direct air capture (DAC) technology. DAC extracts carbon dioxide directly from the air. Oxy CEO Vicki Hollub's goal is to produce \"net-zero\" oil where the CO2 captured in the production of the oil effectively cancels out the emissions produced by using the oil. Hollub believes if DAC fulfills its potential, her company will be able to \"produce oil and gas forever.\" Carbon capture could also open up a massive new opportunity for Occidental and other pioneers. ExxonMobil projects a carbon capture and storage market of $4 trillion by 2050. Unsurprisingly, the oil and gas giant is also investing heavily in the technology. Occidental is potentially at another inflection point as well. Warren Buffett's Berkshire Hathaway currently owns 28% of the company. Buffett has made clear Berkshire doesn't want to acquire Oxy. However, I suspect the conglomerate will continue to aggressively buy shares of the oil producer -- especially considering Berkshire secured regulatory approval to purchase up to 50% of the company. Occidental could become a near-subsidiary of the conglomerate even if doesn't have majority ownership. 2. UiPathI think artificial intelligence (AI) will create many once-in-a-generation investment opportunities. And those opportunities aren't limited to the tech giants that typically capture the headlines. UiPath (PATH -1.52%) is a much smaller company with a market cap of under $11 billion that could be on the threshold of a new era.UiPath is a leader in robotic process automation (RPA). The idea behind RPA is to automate online tasks to improve productivity. RPA isn't new: UiPath was founded in 2005. However, generative AI could be a game-changer that leads to explosive growth. A recent survey UiPath conducted with consulting firm Bain found that 70% of corporate executives believe AI-driven automation is \"very important\" or \"critical\" to the future of their industry. Eighty-four percent of executives believe AI \"will radically change how businesses operate in the next five (5) years.\" UiPath is seizing this opportunity. The company recently launched preview versions of its AI-powered Autopilot for Studio product for developing process automation using natural language and Autopilot for Test Suite to improve productivity in testing. In March, UiPath introduced new generative AI capabilities for its platform. 3. Vertex PharmaceuticalsVertex Pharmaceuticals (VRTX 0.20%) commands a monopoly in treating the underlying cause of cystic fibrosis (CF). It's in the early stages of the commercial launch of the first CRISPR gene-editing therapy, a one-time cure for two rare blood disorders. But those aren't why I think this biotech stock is a once-in-a-generation investment opportunity.The company could have another megablockbuster franchise waiting in the wings in treating pain. Vertex plans to file for regulatory approval of non-opioid pain drug VX-548 this summer and is already preparing for a near-term commercial launch. VX-548 could fill a big gap between anti-inflammatory drugs that are safe but not as effective and opioids that are effective but highly addictive. The biotech is also evaluating other promising non-opioid pain therapies in phase 1 and 2 clinical studies. Vertex recently advanced inaxaplin into phase 3 testing for treating APOL1-mediated kidney disease (AMKD). It hopes to seek accelerated approval if an interim analysis at week 48 of the study looks good. There are no approved therapies that treat the underlying cause of AMKD. The disease affects more patients than CF. There's more. Vertex's pipeline includes programs that hold the potential to cure type 1 diabetes. The company also recently announced the planned acquisition of Alpine Immune Sciences. Alpine expects to advance its lead candidate povetacicept into late-stage testing later this year in treating IgA nephropathy, another disease that affects more patients than CF and with no approved therapies for treating the underlying cause.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429943483"}